Unknown

Dataset Information

0

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.


ABSTRACT: The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages. We developed a retroviral CAR construct specific for the mouse fibroblast activation protein (FAP), comprising a single-chain Fv FAP [monoclonal antibody (mAb) 73.3] with the CD8? hinge and transmembrane regions, and the human CD3? and 4-1BB activation domains. The transduced muFAP-CAR mouse T cells secreted IFN-? and killed FAP-expressing 3T3 target cells specifically. Adoptively transferred 73.3-FAP-CAR mouse T cells selectively reduced FAP(hi) stromal cells and inhibited the growth of multiple types of subcutaneously transplanted tumors in wild-type, but not FAP-null immune-competent syngeneic mice. The antitumor effects could be augmented by multiple injections of the CAR T cells, by using CAR T cells with a deficiency in diacylglycerol kinase, or by combination with a vaccine. A major mechanism of action of the muFAP-CAR T cells was the augmentation of the endogenous CD8(+) T-cell antitumor responses. Off-tumor toxicity in our models was minimal following muFAP-CAR T-cell therapy. In summary, inhibiting tumor growth by targeting tumor stroma with adoptively transferred CAR T cells directed to FAP can be safe and effective, suggesting that further clinical development of anti-human FAP-CAR is warranted.

SUBMITTER: Wang LC 

PROVIDER: S-EPMC4007316 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Wang Liang-Chuan S LC   Lo Albert A   Scholler John J   Sun Jing J   Majumdar Rajrupa S RS   Kapoor Veena V   Antzis Michael M   Cotner Cody E CE   Johnson Laura A LA   Durham Amy C AC   Solomides Charalambos C CC   June Carl H CH   Puré Ellen E   Albelda Steven M SM  

Cancer immunology research 20131112 2


The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages. We developed a retroviral CAR construct specific for the mouse fibroblast activation protein (FAP), comprising a single-chain Fv FAP [monoclonal antibody (mAb) 73.3] with the CD8α hinge and transmembrane regions, and the human CD3ζ and 4-1BB activation domains. The tran  ...[more]

Similar Datasets

| S-EPMC10754280 | biostudies-literature
| S-EPMC6237851 | biostudies-literature
| S-EPMC6076291 | biostudies-literature
| S-EPMC10703879 | biostudies-literature
| S-EPMC2839303 | biostudies-other
| S-EPMC9441337 | biostudies-literature
| S-EPMC8210154 | biostudies-literature
| S-EPMC3734659 | biostudies-literature
| S-EPMC5363190 | biostudies-literature
| S-EPMC4673284 | biostudies-literature